These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 26601962)

  • 1. Neuroprotective Mechanisms Mediated by CDK5 Inhibition.
    Mushtaq G; Greig NH; Anwar F; Al-Abbasi FA; Zamzami MA; Al-Talhi HA; Kamal MA
    Curr Pharm Des; 2016; 22(5):527-34. PubMed ID: 26601962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of CDK5/P25 formation/inhibition in neurodegeneration.
    Camins A; Verdaguer E; Folch J; Canudas AM; Pallàs M
    Drug News Perspect; 2006 Oct; 19(8):453-60. PubMed ID: 17160145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of cyclin-dependent kinase 5 activation by amyloid precursor protein: a novel excitoprotective mechanism involving modulation of tau phosphorylation.
    Han P; Dou F; Li F; Zhang X; Zhang YW; Zheng H; Lipton SA; Xu H; Liao FF
    J Neurosci; 2005 Dec; 25(50):11542-52. PubMed ID: 16354912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology.
    Maccioni RB; Otth C; Concha II; Muñoz JP
    Eur J Biochem; 2001 Mar; 268(6):1518-27. PubMed ID: 11248668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Cdk5 in Alzheimer's Disease.
    Liu SL; Wang C; Jiang T; Tan L; Xing A; Yu JT
    Mol Neurobiol; 2016 Sep; 53(7):4328-42. PubMed ID: 26227906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cdk5: multitasking between physiological and pathological conditions.
    Lopes JP; Agostinho P
    Prog Neurobiol; 2011 Jun; 94(1):49-63. PubMed ID: 21473899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of cyclin-dependent kinase 5 affects early neuroinflammatory signalling in murine model of amyloid beta toxicity.
    Wilkaniec A; Gąssowska-Dobrowolska M; Strawski M; Adamczyk A; Czapski GA
    J Neuroinflammation; 2018 Jan; 15(1):1. PubMed ID: 29301548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implication of cyclin-dependent kinase 5 in the neuroprotective properties of lithium.
    Jordà EG; Verdaguer E; Canudas AM; Jiménez A; Garcia de Arriba S; Allgaier C; Pallàs M; Camins A
    Neuroscience; 2005; 134(3):1001-11. PubMed ID: 15979805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective effect of TNFalpha against the beta-amyloid neurotoxicity mediated by CDK5 kinase.
    Orellana DI; Quintanilla RA; Maccioni RB
    Biochim Biophys Acta; 2007 Feb; 1773(2):254-63. PubMed ID: 17150266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.
    Kesavapany S; Zheng YL; Amin N; Pant HC
    Biotechnol J; 2007 Aug; 2(8):978-87. PubMed ID: 17526058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Roles of cyclin-dependent kinase 5 in central nervous system development and neurodegenerative diseases].
    Chen J; Wang ZF
    Sheng Li Xue Bao; 2010 Aug; 62(4):295-308. PubMed ID: 20717630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide.
    Kesavapany S; Li BS; Amin N; Zheng YL; Grant P; Pant HC
    Biochim Biophys Acta; 2004 Mar; 1697(1-2):143-53. PubMed ID: 15023357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deregulation of cdk5 in Hippocampal sclerosis.
    Sen A; Thom M; Martinian L; Jacobs T; Nikolic M; Sisodiya SM
    J Neuropathol Exp Neurol; 2006 Jan; 65(1):55-66. PubMed ID: 16410749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models.
    Menn B; Bach S; Blevins TL; Campbell M; Meijer L; Timsit S
    PLoS One; 2010 Aug; 5(8):e12117. PubMed ID: 20711428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibition of Cdk5 activity after hypoxia/ischemia injury reduces infarct size and promotes functional recovery in neonatal rats.
    Tan X; Chen Y; Li J; Li X; Miao Z; Xin N; Zhu J; Ge W; Feng Y; Xu X
    Neuroscience; 2015 Apr; 290():552-60. PubMed ID: 25665755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK5 as a therapeutic tool for the treatment of Alzheimer's disease: A review.
    Garemilla S; Kumari R; Kumar R
    Eur J Pharmacol; 2024 Sep; 978():176760. PubMed ID: 38901526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.
    Sun LH; Ban T; Liu CD; Chen QX; Wang X; Yan ML; Hu XL; Su XL; Bao YN; Sun LL; Zhao LJ; Pei SC; Jiang XM; Zong DK; Ai J
    J Neurochem; 2015 Sep; 134(6):1139-51. PubMed ID: 26118667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interplay between the p53 tumor suppressor protein family and Cdk5: novel therapeutic approaches for the treatment of neurodegenerative diseases using selective Cdk inhibitors.
    Schmid G; Strosznajder JB; Wesierska-Gadek J
    Mol Neurobiol; 2006 Aug; 34(1):27-50. PubMed ID: 17003520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Cdk5 activity in neuronal degeneration and regeneration.
    Kanungo J; Zheng YL; Amin ND; Pant HC
    Cell Mol Neurobiol; 2009 Dec; 29(8):1073-80. PubMed ID: 19455415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinase 5 in neurofilament function and regulation.
    Kesavapany S; Li BS; Pant HC
    Neurosignals; 2003; 12(4-5):252-64. PubMed ID: 14673212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.